Natera, Inc. Product revenues — Total revenues increased by 4.9% to $693.87M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 38.8%, from $500.04M to $693.87M. Over 4 years (FY 2021 to FY 2025), Product revenues — Total revenues shows an upward trend with a 41.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market share, higher test volume, or successful expansion of the product portfolio, while a decrease may signal competitive pressure or reduced demand for diagnostic services.
This metric represents the total gross revenue generated specifically from the sale of diagnostic testing products and a...
Comparable to product-specific revenue lines in other molecular diagnostic or life sciences companies, often benchmarked against total diagnostic test volume growth.
ntra_segment_product_revenues_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $137.23M | $150.65M | $160.88M | $190.00M | $194.58M | $199.83M | $212.89M | $237.80M | $258.26M | $265.22M | $307.25M | $364.67M | $411.36M | $436.13M | $472.91M | $500.04M | $544.43M | $590.20M | $661.16M | $693.87M |
| QoQ Change | — | +9.8% | +6.8% | +18.1% | +2.4% | +2.7% | +6.5% | +11.7% | +8.6% | +2.7% | +15.8% | +18.7% | +12.8% | +6.0% | +8.4% | +5.7% | +8.9% | +8.4% | +12.0% | +4.9% |
| YoY Change | — | — | — | — | +41.8% | +32.6% | +32.3% | +25.2% | +32.7% | +32.7% | +44.3% | +53.4% | +59.3% | +64.4% | +53.9% | +37.1% | +32.3% | +35.3% | +39.8% | +38.8% |